Teva, Impax To Pull Generic Wellbutrin After FDA Finding

Law360, New York (October 4, 2012, 9:23 PM EDT) -- The U.S. Food and Drug Administration said Wednesday that Teva Pharmaceuticals USA Inc. and Impax Laboratories Inc. would remove a generic version of the antidepressant Wellbutrin XL from the market following the agency's determination it is not equivalent to the brand-name version.

New data shows that the 300-milligram dose of Budeprion XL, manufactured by Impax and marketed by Teva, is not therapeutically equivalent to the same dose of GlaxoSmithKline's Wellbutrin XL, according to the FDA.

Impax and Teva have stopped shipping the drug, and Impax asked...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.